Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김이준 | - |
dc.date.accessioned | 2022-02-21T16:30:08Z | - |
dc.date.available | 2022-02-21T16:30:08Z | - |
dc.date.issued | 2022 | - |
dc.identifier.issn | 2045-7022 | - |
dc.identifier.other | OAK-30934 | - |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/260510 | - |
dc.description.abstract | Background: Several type B adverse drug reactions (ADRs), especially severe cutaneous adverse reactions (SCARs), are associated with particular human leukocyte antigen (HLA) genotypes. However, pre-stored HLA information obtained from other clinical workups has not been used to prevent ADRs. We aimed to simulate the preemptive use of pre-stored HLA information in electronic medical records to evaluate whether this information can prevent ADRs. Methods: We analyzed the incidence and the risk of ADRs for selected HLA alleles (HLA-B*57:01, HLA-B*58:01, HLA-A*31:01, HLA-B*15:02, HLA-B*15:11, HLA-B*13:01, HLA-B*59:01, and HLA-A*32:01) and seven drugs (abacavir, allopurinol, carbamazepine, oxcarbazepine, dapsone, methazolamide, and vancomycin) using pre-stored HLA information of transplant patients based on the Pharmacogenomics Knowledge Base guidelines and experts' consensus. Results: Among 11,988 HLA-tested transplant patients, 4092 (34.1%) had high-risk HLA alleles, 4583 (38.2%) were prescribed risk drugs, and 580 (4.8%) experienced type B ADRs. Patients with HLA-B*58:01 had a significantly higher incidence of type B ADR and SCARs associated with allopurinol use than that of patients without HLA-B*58:01 (17.2% vs. 11.9%, odds ratio [OR] 1.53 [95% confidence interval {CI} 1.09–2.13], p = 0.001, 2.3% versus 0.3%, OR 7.13 [95% CI 2.19–22.69], p < 0.001). Higher risks of type B ADR and SCARs were observed in patients taking carbamazepine or oxcarbazepine if they had one of HLA-A*31:01, HLA-B*15:02, or HLA-B*15:11 alleles. Vancomycin and dapsone use in HLA-A*32:01 and HLA-B*13:01 carriers, respectively, showed trends toward increased risk of type B ADRs. Conclusion: Utilization of pre-stored HLA data can prevent type B ADRs including SCARs by screening high-risk patients. © 2022 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology. | - |
dc.language | English | - |
dc.publisher | John Wiley and Sons Inc | - |
dc.subject | humanes leukozytenantigen | - |
dc.subject | pharmakogenomik | - |
dc.subject | präventive genotypisierung | - |
dc.subject | uberempfindlichkeit | - |
dc.subject | unerwünschte arzneimittelwirkung | - |
dc.title | Reducing severe cutaneous adverse and type B adverse drug reactions using pre-stored human leukocyte antigen genotypes | - |
dc.type | Article | - |
dc.relation.issue | 1 | - |
dc.relation.volume | 12 | - |
dc.relation.index | SCIE | - |
dc.relation.index | SCOPUS | - |
dc.relation.journaltitle | Clinical and Translational Allergy | - |
dc.identifier.doi | 10.1002/clt2.12098 | - |
dc.identifier.wosid | WOS:000747683100005 | - |
dc.identifier.scopusid | 2-s2.0-85123752678 | - |
dc.author.google | Lee K.H. | - |
dc.author.google | Kang D.Y. | - |
dc.author.google | Kim H.H. | - |
dc.author.google | Kim Y.J. | - |
dc.author.google | Kim H.J. | - |
dc.author.google | Kim J.H. | - |
dc.author.google | Song E.Y. | - |
dc.author.google | Yun J. | - |
dc.author.google | Kang H.-R. | - |
dc.contributor.scopusid | 김이준(56714252700) | - |
dc.date.modifydate | 20230118115726 | - |